Mumbai, June 1 -- Investor sentiment has remained strong following regulatory milestones for the drug. The stock has rallied 37.58% over the past week, surged 61.72% in the last month and gained 58.63% so far in 2026.

The novel intravenous antibiotic is indicated for the treatment of adults with complicated urinary tract infections (cUTI), including pyelonephritis.

The approval marks a major milestone for the Mumbai-based drug maker, coming just days after the antibiotic received marketing approval in India on 27 May 2026. According to the company, ZAYNICH is the first new chemical entity fully discovered, developed and commercialised by an Indian pharmaceutical company to secure U.S. FDA approval.

ZAYNICH combines cefepime, a fourth-g...